T1	PROC 59 115	evaluar el efecto de la reducción progresiva de la dosis
T2	CHEM 119 129	filgotinib
#1	AnnotatorNotes T2	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T3	LIVB 133 142	pacientes
#2	AnnotatorNotes T3	C0030705; Patients; Patient or Disabled Group
T4	DISO 147 163	colitis ulcerosa
#3	AnnotatorNotes T4	C0009324; Ulcerative Colitis; Disease or Syndrome
T5	PROC 198 259	Estudio aleatorizado, doble ciego, controlado y multicéntrico
T6	PROC 265 338	evaluar la eficacia y la seguridad de la reducción progresiva de la dosis
T7	CHEM 342 352	filgotinib
#4	AnnotatorNotes T7	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T8	Route 370 378	vía oral
T9	LIVB 382 391	pacientes
#5	AnnotatorNotes T9	C0030705; Patients; Patient or Disabled Group
T10	DISO 396 412	colitis ulcerosa
#6	AnnotatorNotes T10	C0009324; Ulcerative Colitis; Disease or Syndrome
T11	DISO 456 472	colitis ulcerosa
#7	AnnotatorNotes T11	C0009324; Ulcerative Colitis; Disease or Syndrome
T12	LIVB 505 514	pacientes
#8	AnnotatorNotes T12	C0030705; Patients; Patient or Disabled Group
T13	Date 578 589	actualmente
T14	PROC 590 601	tratamiento
#9	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	Dose 606 612	200 mg
T16	CHEM 616 626	filgotinib
#10	AnnotatorNotes T16	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T17	Frequency 630 632	/d
T18	DISO 688 692	pMCS
T19	PROC 727 734	visitas
T20	Frequency 735 747	trimestrales
T21	Neg_cue 847 850	sin
T22	CHEM 851 868	corticoesteroides
#11	AnnotatorNotes T22	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T23	Negated 851 868	corticoesteroides
T24	Duration 877 896	al menos 12 semanas
T25	PROC 929 932	CPF
T26	PROC 958 969	observación
#12	AnnotatorNotes T26	C0302523; Observation in research; Research Activity | C0700325; Patient observation; Health Care Activity
T27	PROC 973 975	PE
#13	AnnotatorNotes T27	C0015260; Exercise stress test; Diagnostic Procedure
T28	PROC 982 996	sigmoidoscopia
#14	AnnotatorNotes T28	C0037075; Sigmoidoscopy (procedure); Diagnostic Procedure
T29	LIVB 1048 1057	pacientes
#15	AnnotatorNotes T29	C0030705; Patients; Patient or Disabled Group
T30	PHYS 1075 1083	concebir
#16	AnnotatorNotes T30	C0009637; Conception; Organism Function
T31	Neg_cue 1109 1117	negativo
T32	PROC 1125 1143	prueba de embarazo
#17	AnnotatorNotes T32	C0032976; Pregnancy Tests; Diagnostic Procedure
T33	Negated 1135 1143	embarazo
T34	PROC 1164 1208	gonadotropina coriónica humana beta en suero
T35	Frequency 1257 1269	mensualmente
T36	PROC 1276 1294	prueba de embarazo
#18	AnnotatorNotes T36	C0032976; Pregnancy Tests; Diagnostic Procedure
T37	PROC 1299 1321	tira reactiva de orina
T38	PROC 1333 1344	tratamiento
#19	AnnotatorNotes T38	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T39	CHEM 1349 1359	filgotinib
#20	AnnotatorNotes T39	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T40	LIVB 1367 1394	pacientes de sexo masculino
T41	LIVB 1401 1427	pacientes de sexo femenino
T42	PHYS 1445 1453	concebir
#21	AnnotatorNotes T42	C0009637; Conception; Organism Function
T43	PROC 1478 1501	métodos anticonceptivos
#22	AnnotatorNotes T43	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T44	PROC 1549 1558	protocolo
#23	AnnotatorNotes T44	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T45	Neg_cue 1579 1585	evitar
T46	CHEM 1594 1648	vacunas elaboradas con microorganismos vivos atenuados
T47	Negated 1594 1648	vacunas elaboradas con microorganismos vivos atenuados
T48	Duration 1678 1688	12 semanas
T49	CHEM 1713 1723	filgotinib
#24	AnnotatorNotes T49	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T50	DISO 1843 1866	afección médica crónica
T51	Duration 1859 1866	crónica
T52	DISO 1881 1891	neumopatía
#25	AnnotatorNotes T52	C0024115; Lung diseases; Disease or Syndrome
T53	DISO 1894 1905	cardiopatía
#26	AnnotatorNotes T53	C0018799; Heart Diseases; Disease or Syndrome
T54	DISO 1907 1918	alcoholismo
#27	AnnotatorNotes T54	C0001973; Alcoholic Intoxication, Chronic; Mental or Behavioral Dysfunction
T55	DISO 1921 1933	drogadicción
#28	AnnotatorNotes T55	C1510472; Drug Dependence; Mental or Behavioral Dysfunction
T56	LIVB 1955 1967	investigador
#29	AnnotatorNotes T56	C0035173; Research Personnel; Professional or Occupational Group
T57	LIVB 1995 2003	paciente
#30	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	Neg_cue 2004 2006	no
T59	Negated 2011 2031	apto para el estudio
T60	Neg_cue 2034 2040	impida
T61	Negated 2044 2070	cumplimiento del protocolo
T62	PROC 2044 2070	cumplimiento del protocolo
#31	AnnotatorNotes T62	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T63	LIVB 2087 2095	paciente
#32	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T64	DISO 2102 2119	hipersensibilidad
#33	AnnotatorNotes T64	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T65	CHEM 2135 2161	ingredientes de filgotinib
T66	DISO 2184 2201	reacción alérgica
#34	AnnotatorNotes T66	C0020517; Hypersensitivity; Pathologic Function | C1527304; Allergic Reaction; Pathologic Function
T67	CHEM 2222 2248	ingredientes de filgotinib
T68	LIVB 2277 2289	investigador
#35	AnnotatorNotes T68	C0035173; Research Personnel; Professional or Occupational Group
T69	LIVB 2293 2335	Mujer embarazada o en período de lactancia
T70	PHYS 2379 2388	amamantar
#36	AnnotatorNotes T70	C0006147; Breast Feeding; Organism Function
T71	PROC 2429 2437	donación
T72	PROC 2440 2460	extracción de óvulos
T73	PHYS 2474 2485	fecundación
#37	AnnotatorNotes T73	C0015914; Fertilization; Organism Function
T74	Date 2486 2492	actual
T75	Date 2495 2501	futura
T76	LIVB 2552 2559	Hombres
#38	AnnotatorNotes T76	C0025266; Male population group; Population Group | C0086418; Homo sapiens; Human
T77	Neg_cue 2564 2566	no
T78	PROC 2600 2611	donar semen
T79	Negated 2600 2611	donar semen
T80	Duration 2620 2636	al menos 90 días
T81	Date 2651 2663	última dosis
T82	CHEM 2668 2693	producto en investigación
T83	CHEM 2695 2698	PEI
T84	LIVB 2706 2714	paciente
#39	AnnotatorNotes T84	C0030705; Patients; Patient or Disabled Group
T85	Neg_cue 2726 2728	no
T86	Negated 2746 2775	cumplir con las restricciones
T87	CHEM 2791 2801	medicación
#40	AnnotatorNotes T87	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T88	PROC 2854 2863	protocolo
#41	AnnotatorNotes T88	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T89	LIVB 2870 2878	paciente
#42	AnnotatorNotes T89	C0030705; Patients; Patient or Disabled Group
T90	PROC 2913 2953	prueba de tuberculosis (TB) QuantiFERON®
T91	PROC 3006 3030	prueba de TB QuantiFERON
T92	PROC 3049 3077	interrupción del tratamiento
T93	CHEM 3085 3088	PEI
T94	DISO 3108 3125	neoplasia maligna
#43	AnnotatorNotes T94	C0006826; Malignant Neoplasms; Neoplastic Process | C1306459; Primary malignant neoplasm; Neoplastic Process
T95	Neg_cue 3127 3134	excepto
T96	LIVB 3135 3144	pacientes
#44	AnnotatorNotes T96	C0030705; Patients; Patient or Disabled Group
T97	Negated 3135 3144	pacientes
T98	PROC 3145 3153	tratados
T99	DISO 3181 3195	cáncer de piel
#45	AnnotatorNotes T99	C0007114; Malignant neoplasm of skin; Neoplastic Process | C0699893; Skin carcinoma; Neoplastic Process
T100	Negated 3196 3204	distinto
T101	Negated 3209 3217	melanoma
#46	AnnotatorNotes T101	C0025202; melanoma; Neoplastic Process
T102	DISO 3223 3255	carcinoma cervicouterino in situ
#47	AnnotatorNotes T102	C0851140; Carcinoma in situ of uterine cervix; Neoplastic Process
T103	Negated 3223 3255	carcinoma cervicouterino in situ
T104	LIVB 3262 3270	paciente
#48	AnnotatorNotes T104	C0030705; Patients; Patient or Disabled Group
T105	PROC 46 53	Estudio
T106	PROC 813 822	selección
T107	PROC 1221 1230	selección
T108	PROC 1660 1667	estudio
T109	PROC 1730 1737	estudio
T110	LIVB 1973 1981	promotor
T111	PHYS 2363 2373	embarazada
T112	PROC 2514 2521	estudio
T113	DISO 3209 3217	melanoma
T114	PROC 3295 3319	interrupción del estudio
T115	Dose 627 630	1 v
T116	PROC 2960 2969	selección
T117	Observation 70 76	efecto
T118	Observation 167 175	remisión
T119	Observation 416 432	remisión clínica
T120	Observation 521 545	participar en el estudio
T121	Observation 673 681	remisión
T122	Quantifier_or_Qualifier 716 726	al menos 2
T123	Quantifier_or_Qualifier 748 760	consecutivas
T124	CONC 907 913	inicio
T125	Result_or_Value 933 944	<= 250 µg/g
T126	Quantifier_or_Qualifier 951 957	última
T127	Result_or_Value 1000 1005	0 o 1
T128	Result_or_Value 1099 1117	resultado negativo
T129	Quantifier_or_Qualifier 1144 1162	altamente sensible
T130	Quantifier_or_Qualifier 1502 1520	altamente eficaces
T131	Observation 1562 1573	Disposición
T132	Quantifier_or_Qualifier 1602 1648	elaboradas con microorganismos vivos atenuados
T133	CONC 1697 1709	última dosis
T134	Observation 2011 2031	apto para el estudio
T135	Observation 2044 2070	cumplimiento del protocolo
T136	Quantifier_or_Qualifier 2202 2215	significativa
T137	Observation 2341 2373	intención de quedarse embarazada
T138	Observation 2379 2388	amamantar
T139	Quantifier_or_Qualifier 2404 2412	previsto
T140	CONC 2533 2538	final
T141	Observation 2573 2583	dispuestos
T142	CONC 2651 2663	última dosis
T143	Observation 2734 2743	dispuesto
T144	Quantifier_or_Qualifier 2811 2823	concomitante
T145	Result_or_Value 2888 2906	resultado positivo
T146	Result_or_Value 2974 2999	resultados indeterminados
T147	Observation 3295 3319	interrupción del estudio
T148	Patient 133 142	pacientes
T149	Patient 382 391	pacientes
T150	Patient 505 514	pacientes
T151	Patient 1048 1057	pacientes
T152	Patient 1367 1394	pacientes de sexo masculino
T153	Patient 1401 1427	pacientes de sexo femenino
T154	History_of 1713 1723	filgotinib
T155	Other 1955 1967	investigador
T156	Patient 1995 2003	paciente
T157	Patient 2087 2095	paciente
T158	History_of 2102 2119	hipersensibilidad
T159	History_of 2184 2201	reacción alérgica
T160	Other 2277 2289	investigador
T161	Patient 2293 2335	Mujer embarazada o en período de lactancia
T162	Future 2363 2373	embarazada
T163	Future 2429 2437	donación
T164	Future 2440 2460	extracción de óvulos
T165	Future 2474 2485	fecundación
T166	Patient 2552 2559	Hombres
T167	Patient 2706 2714	paciente
T168	History_of 2791 2801	medicación
T169	Patient 2870 2878	paciente
T170	History_of 3108 3125	neoplasia maligna
T171	Patient 3135 3144	pacientes
T172	History_of 3145 3153	tratados
T173	History_of 3181 3195	cáncer de piel
T174	History_of 3209 3217	melanoma
T175	History_of 3223 3255	carcinoma cervicouterino in situ
T176	Patient 3262 3270	paciente
T177	Future 2379 2388	amamantar
